Biotech Hangout cover image

Episode 78

Biotech Hangout

00:00

Conflicting Data and Potential Delays for a Radio Pharmaceutical in Prostate Cancer Treatment

This chapter explores Novartis' groundbreaking radio pharmaceutical for prostate cancer, targeting p p sma. It discusses conflicting data on the drug's efficacy, with impressive progression-free survival (PFS) data but currently unfavorable overall survival (OS) data. The speaker anticipates further analysis to unveil the drug's true effectiveness, attributing the discrepancy to patient crossover.

Transcript
Play full episode

The AI-powered Podcast Player

Save insights by tapping your headphones, chat with episodes, discover the best highlights - and more!
App store bannerPlay store banner
Get the app